NDAINTRAVENOUSSOLUTION
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE (diltiazem hydrochloride) by R-Pharm US is muscle. Approved for atrial flutter, atrial fibrillation, atrial fibrillation. First approved in 2025.
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Diltiazem hydrochloride in 0.72% sodium chloride is an intravenous calcium channel antagonist indicated for rapid ventricular rate control in atrial fibrillation, atrial flutter, and conversion of paroxysmal supraventricular tachycardia to normal sinus rhythm. It works by slowing AV nodal conduction and prolonging AV nodal refractoriness, with frequency-dependent effects that selectively reduce heart rate during tachycardias.
Growth
Recently approved IV antiarrhythmic in growth phase; R-Pharm US will likely expand commercial infrastructure to capture acute care and hospital formulary adoption.
Mechanism of Action
muscle. Paroxysmal Supraventricular Tachycardia: Diltiazem slows AV nodal conduction time and prolongs AV nodal refractoriness. Diltiazem exhibits frequency- (use-) dependent effects on AV nodal conduction such that it may selectively reduce the heart rate during tachycardias involving the AV node…
Indications (2)
Worked on DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.